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Poster Session I S223million/kg single dose on day 2 after HSCT (n 5 18), or in repeat
doses of 1 or 5 M/kg on days 2, 9, 16, or 5 M/kg on days 2, 9, 16,
23 and 30 (n 5 18).
Table 1. MultiStem dose escalation strategy
Single dose Arm Repeat dose Arm (Days 2, 9, 16
(Day 2 after HSCT) or 2, 9, 16, 23 and 30 after HSCT)1 Million cells/kg 1 Million cells/kg  3 infusions
5 Million cells/kg 5 Million cells/kg  3 infusions
10 Million cells/kg 5 Million cells/kg  5 infusionsInfusional toxicity and RRTs are assessed as safety parameters for 30
days after the last MultiStem dose. Secondary evaluations include in-
cidences of Grade III/IV acute GVHD and infection and survival
through day 100. Dose assignment is guided by the Continual Reas-
sessment Method.
Results: Single dose arm; 15 patients were enrolled from 4 clinical
centers. Multistem was infused at 1, 5 and 10 million/kg. At this
point there has been no observation of infusional toxicity. Enroll-
ment is scheduled for completion by December 2010. Repeat dose
arm; appr. half of the multiple dose cohorts to be enrolled at this
time. Details of primary endpoints and preliminary results for sec-
ondary endpoints will be presented for the single dose arm.
Summary:This Phase 1 trial of the stromal stem cell productMulti-
Stem is focused on safety of repeated infusion during the first weeks
after HSCT, the critical period for engraftment with high risk for
first onset of aGVHD. This strategy will be exploited to determine
if MultiStem therapy can be harnessed for a potential new therapeu-
tic option for GVHD prophylaxis after HSCT.190
INTERCELLULAR CYTOSOLIC TRANSFER CORRELATESWITHMESENCHY-
MAL STROMAL CELL (MSC) RESCUE OF UMBILICAL CORD BLOOD (UCB)
CELL VIABILITY DURING EX VIVO UCB EXPANSION
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Mesenchymal Stromal Cell (MSC) co-culture enhances ex vivo ex-
pansion of hematopoietic stem and progenitor cells from thawed
Umbilical Cord Blood (UCB) without prior CD341/CD1331 cell
selection. We hypothesized that the superior ex vivo expansion is
due to reversal of UCB c apoptosis via intercellular cytosolic transfer
from the MSC to the UCB cells. MSC endogenously expressing
green fluorescent protein (GFP) or exogenously labeled with quan-
tumdots (QDs)were co-culturedwithUCBcells positive for a hema-
topoietic-specific CD45 marker. Cultured UCB cells without MSC
layer served as control. Annexin-V, JC-1 dye & caspase inhibitors
were used to investigatemitochondria-associated apoptosis pathway.
Flow cytometry & confocal imaging were used to detect for the
transfer of the GFP or QD in co-cultured UCB cells. Thawed
UCB cells had high percentage of early apoptotic cells (defined by
Annexin-V positivity) which progressed to dead cells (defined by
7AAD positivity). MSC co-culture resulted in reversal of Annexin-
V positivity and reached a maximum on day 3 (viability defined by
double negative staining for Annexin-V and 7AAD) (p\0.05). A sig-
nificant reduction in caspase 3/7, 8& 9 activity as well as preservation
of mitochondrial membrane potential were observed in the co-cul-
tured UCB cells (p\ 0.05). Upon co-culture with GFP-expressing
or QD-labelled MSC, unlabelled UCB cells were found positive
for these markers as early as 24 hours post co-culture. The number
of GFP & CD45 positive UCB cells increased over the first 3 days
of co-culturing, which correlated with viability increase. Direct con-
tact betweenMSC&UCB was necessary for the transfer, as negligi-
ble transfer was observed when the two populations were separated
by transwell inserts. Separation also showed a significant decrease
in viability. The UCB cells that tightly adhered to the MSC layer
exhibited optimal transfer & cell viability. DNA analysis of the via-
ble, GFP transfer-positive UCB cells, as determined by VariableNumber Tandem Repeat analysis ruled out the possibilities of
MSC trans-differentiation or MSC-UCB fusion. In addition, there
was statistical correlation between higher levels of cytosolic transfer
and enhanced UCB cell viability (p \ 0.0001). The above data
provides evidence that intercellular transfer of cytosolic materials
could be one novel mechanism preventing UCB cell death in MSC
co-culture.HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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CLINICAL OUTCOMES OF HAPLOIDENTICAL DONOR COMPARED WITH
UNRELATED AND HLA-MATCHED RELATED DONOR HEMATOPOIETIC
STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES
Luo, Y., Tan, Y., Hu, Y., Shi, J., Zheng, G., Zheng, W., Huang, H.
The First Affiliated Hospital, Zhejiang University School of Medicine,
Hangzhou, Zhejiang Province, China
Introduction: In clinical trials, an HLA-matched donor can be
found for about 50% to 60% of patients referred for HSCT which
greatly limits the application of allogeneic HSCT. Haploidentical
HSCTwould increase the availability of a donor to 100%.However,
haploidentical HSCTmay be associated with high risks of complica-
tions, such as graft rejection, severe GVHD and infection etc. Much
progress have been made due to advanced technologies applied in
haploidentical HSCT.
Materials and Methods: For haploidentical HSCT, conditioning
regimen consisted of Ara-C (4 g/m2/d) on day -10 and -9, Bu
(9.6mg/kg) on day -8, -7 and -6, Cy (1.8 g/m2/d) on day -5 and -4,
Me-CCNU (250 mg/kg) on day -3, and ATG (2.5 mg/kg/d) on
day -5 to -2. For unrelated and matched related HSCT, the condi-
tioning regimen consisted of Bu (0.8mg/kg -7d to -4d), Cy (60mg/
kg /d -3d and -2d). GVHD prophylaxis consisted of cyclosporine
A (CsA), mycophenolate mofetil (MMF), and short-termmethotrex-
ate while ATG were added in HLA-mismatched unrelated HSCT.
The data of 114 patients (38 with haploidentical donors, 35 with
HLA-matched related donors and 63 with unrelated donors) were
analyzed .
Results: The incidence of grade II–IV aGVHD was 36.8% in the
haploidentical group, 40.5% in the unrelated group and 22.9% in
the related matched group (p. 0.05 between haploidentical and un-
related, haloidentical and related matched group; p 5 0.0477 be-
tween urelated and related matched group). The 1 year OS were
68.4%, 78.4% and 91.3% in haploidentical, unrelated and relate
matched group respectively(p . 0.05 among the 3 groups). The 1
year TRM were 15.8%, 6.3% and 0% in haploidentical, unrelated
and related matched group respectively(p\0.0162 between haploi-
dentical and relatedmatched group; p. 0.05 between haploidentical
and unrelated, unrelated and matched related group).
Conclusions: There is a trend that survival in haploidentical group
and unrelated group is inferior to matched related group in patients
despite of statistical insignificance. AnHLA-matchedHSCT is com-
monly the preferred transplantation and donors fromHLA-matched
related siblings are usually the first choice. Haploidentical stem cell
transplantation is relatively safe and efficient for patients who do not
have HLA matched donors.192
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Background: Haploidentical (haplo) stem cell transplantation has
demonstrated intensive graft vs. leukemia effect and survival advan-
tage in patients with advanced leukemia. However, early virus reac-
tivation and acute GVHD may dramatically increase the cost of
treatment. Here we investigate the impact of donor types on clinical
outcomes and cost of treatment within 100 days of transplant.
